Abstract 99P
Background
Immune checkpoint inhibitors (CPI) induced diarrhoea and colitis (ir-colitis) are common immune-related adverse events. Ir-colitis management guidelines are based on expert consensus. This retrospective study presents real-world data on melanoma patients with ir-colitis requiring medical intervention. The objective was to describe treatment patterns, hypothesising that glucocorticoid (GC) use exceeds guidelines and that biologic treatment (BIOx) initiation is often delayed.
Methods
Melanoma patients treated with CPI (anti-PD-1 and/or anti-CTLA4) in Southern Denmark (2013–2023) were identified from the Danish metastatic melanoma database. A validated AI language model was employed for identification of ir-colitis patients. Patient and treatment characteristics were analysed based on CPI regimen, CTCAE grade, sex, age, GC use, BIOx, and GC tapering failure.
Results
In 85 included patients (120 expected in the final cohort), predominantly female (n=47), the median (Mdn) age was 69 years (SD = 13.5), with 52% experiencing grade IV ir-colitis. Anti-CTLA4 regimens were the most common triggers, with 39% receiving monotherapy and 29% combination therapy. Forty-three patients achieved remission on GC alone, with Mdn prednisolone (PRED) dose of 1025 mg (IQR 600-1638). Among BIOx patients (n=38), the Mdn PRED dose was 2991 mg (IQR 1965-4403), with a Mdn interval of 17 days from GC initiation to BIOx. Infliximab was used in all BIOx patients; 11 required a second dose, and three needed a third. Mdn duration from GC initiation to complete tapering was 35 days (IQR 22-43) without BIOx and 65 days (IQR 49-93) with BIOx. Mdn duration from BIOx initiation to complete tapering was 45 days (IQR 29-67). Forty-two patients experienced failure during tapering, with Mdn GC usage of 2650 mg (IQR 1543-4403); among BIOx patients (n=24), Mdn GC usage was 3354 mg (IQR 2176-5027). In addition, peak GC dose and ir-colitis’s impact on survival compared with matched controls will be presented.
Conclusions
BIOx was required in 45% of cases, highlighting the need for optimised ir-colitis management by addressing excessive GC use and delayed initiation of BIOx. Further prospective studies are warranted, awaiting results from ongoing randomized clinical trials (e.g. NCT05947669).
Editorial acknowledgement
AI-assisted technology (ChatGPT-4) was used to improve the readability of the abstract at a final stage of abstract editing. After using these services, the authors reviewed and edited the content as needed and take full responsibility for the content of the abstract.
Legal entity responsible for the study
Department of Oncology, Odense University Hospital.
Funding
The research salary of SK(main author) were granted as part of his PhD. Grants were obtained by the Odense University Hospitals PhD fund and PhD fund of the Region of Southern Denmark. The Danish metastatic melanoma database is supported by Bristol Myers Squibb, Roche, Novartis, MSD, and Pierre Fabre. The funding bodies did not have any other role in the study.
Disclosure
C.H. Ruhlmann: Financial Interests, Personal, Invited Speaker: Bristol Myers Squibb, Helsinn Healthcare, MSD, Pharmanovia; Financial Interests, Personal, Other, Consultant: Astellas Pharma; Financial Interests, Institutional, Coordinating PI, Funding for a clinical trial; Helsinn Healthcare, Novo Nordisk Foundation. All other authors have declared no conflicts of interest.
Resources from the same session
135P - Efficacy and safety of tislelizumab combined with bronchial arterial infusion (BAI) chemotherapy in potentially resectable stage IIIB non-small cell lung cancer(NSCLC): A prospective, single-arm phase II clinical study
Presenter: Xu Ma
Session: Poster Display session
Resources:
Abstract
136P - Tislelizumab (TIS) plus chemotherapy (chemo) with or without bevacizumab (beva) for patients with EGFR-mutated nonsquamous NSCLC (nsq-NSCLC) after progression on EGFR tyrosine kinase inhibitor (TKI) therapy: An updated analysis
Presenter: Baohui Han
Session: Poster Display session
Resources:
Abstract
137P - Hepatic arterial infusion chemotherapy combined with lenvatinib and tislelizumab for unresectable hepatocellular carcinoma: A single-arm, phase II study
Presenter: Jianbing Wu
Session: Poster Display session
Resources:
Abstract
138P - Interim results of neoadjuvant TACE plus lenvatinib and tislelizumab in resectable HCC at CNLC stages IB and IIA with high-risk of recurrence: A prospective, single-arm, phase II trial
Presenter: Yuhua Zhang
Session: Poster Display session
Resources:
Abstract
139P - Ablation combined with tislelizumab in treating hepatocellular carcinoma: A phase II trial
Presenter: Yangxun Pan
Session: Poster Display session
Resources:
Abstract
140P - Tislelizumab combined with lenvatinib and transarterial chemoembolization(TACE) neoadjuvant treatment in resectable CNLC IIa-IIb hepatocellular carcinoma: A prospective, single-arm, phase II study
Presenter: Zhibo Zhang
Session: Poster Display session
Resources:
Abstract
141P - Efficacy and safety of tislelizumab(T) combined with gemcitabine and cisplatin(GC) for patients with localized muscle-invasive bladder cancer(MIBC) after radical local surgery: A prospective, phase II study
Presenter: Ming Cao
Session: Poster Display session
Resources:
Abstract
143P - Strength of patient (pt) preference for atezolizumab (atezo) subcutaneous (SC) vs intravenous (IV) for the treatment of NSCLC: exploratory analyses from the IMscin002 study
Presenter: Margarita Majem Tarruella
Session: Poster Display session
Resources:
Abstract
144P - First-line cemiplimab monotherapy for advanced non-small cell lung cancer (NSCLC) of squamous histology: Subgroup analysis with 5-year results from EMPOWER-Lung 1
Presenter: Tamta Makharadze
Session: Poster Display session
Resources:
Abstract
145P - Penpulimab-based combination neoadjuvant/adjuvant therapy for patients with resectable locally advanced non-small cell lung cancer: An update of the phase II, prospective study (ALTER-L043)
Presenter: Changli Wang
Session: Poster Display session
Resources:
Abstract